Papers/PMID:25092108
Effects of L-carnitine supplementation on oxidative stress and antioxidant enzymes activities in patients with coronary artery disease: a randomized, placebo-controlled trial.
Nutrition journal2014The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
(R)-carnitine — decreases malondialdehyde (circulating)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The subjects in the LC group had significantly lower level of MDA (1.8 ± 0.3 versus 2.0 ± 0.4 μmol/L, P = 0.01), higher levels of LC (40.0 ± 12.0 versus 35.2 ± 12.0 μmol/L, P = 0.02), and higher activities of CAT (13.1 ± 5.8 versus 10.6 ± 2.9 U/mg of protein, P < 0.01), SOD (20.7 ± 4.2 versus 13.1 ± 2.9 U/mg of protein, P < 0.01), and GPx (23.0 ± 3.1 versus 19.1 ± 2.3 U/mg of protein, P < 0.01) than those in the placebo group at week 12.”
Quoted verbatim from Effects of L-carnitine supplementation on oxidative stress and antioxidant enzymes activities in patients with coronary artery disease: a randomized, placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 1000 mg/day L-carnitine as 500 mg twice daily for 12 weeks
- Population
- Male patients with coronary artery disease (at least 50% stenosis of a major coronary artery), 39 completers, week 12 values compared with starch placebo; single-blind
Effects of L-carnitine supplementation on oxidative stress and antioxidant enzymes activities in patients with coronary artery disease: a randomized, placebo-controlled trial.2014PMID:25092108Permalink